



## **HOSPITAL GRANT AGREEMENT**

This Grant Agreement (“**Agreement**”) is entered into as of 18<sup>th</sup> Feb 2019 (“**Effective Date**”) by and between Novartis Healthcare A/S, Reg. No. 20575786, a company incorporated under the laws of Denmark, located at Edvard Thomsens Vej 14, DK-2300 Copenhagen S, Denmark (“**Novartis**”) and Bispebjerg og Frederiksberg Hospital, a public hospital within the legal entity of Region Hovedstaden (the Capital Region of Denmark), represented by professor, consultant, dr.med. Simon Francis Thomsen, an Organization incorporated under the laws of Denmark, located at Bispebjerg Hospital, Dermatologisk afdeling, Bispebjerg Bakke 23, Nielsine Nielsens Vej 9, Indgang 4, 2. sal, 2400 København NV (“**Grant Recipient**”). Novartis and Grant Recipient may hereinafter be referred to individually as a “**Party**” and collectively as the “**Parties**”.

WHEREAS, Grant Recipient has specifically requested Novartis’ financial contribution in order to support the Grant Activity (as defined in Exhibit A), through a Grant Request Letter, which is attached hereto as Exhibit B;

WHEREAS, in accordance with the Grant Request Letter mentioned above, Novartis wishes to support the Grant Activity with the grant amount or grant in-kind (“Grant”) (as defined in Exhibit A); and

WHEREAS, Grant Recipient accepts the Grant subject to the terms and conditions of this Agreement.

NOW THEREFORE, in consideration of the premises and the mutual covenants herein contained, it is mutually agreed as follows:

### **1. GRANT BY NOVARTIS**

- 1.1 **Grant.** Novartis will provide the Grant as set forth in Exhibit A solely to support Grant Recipient in performing the Grant Activity as set forth in Exhibit A in accordance with agreed timelines if any.
- 1.2 **Statement of Purpose.** The Grant Activity is for scientific and/or educational purposes only and will not promote Novartis’ products, directly or indirectly. The Grant is not being given in exchange for any explicit or implicit agreement to purchase, prescribe, recommend, influence or provide favorable formulary status for any of Novartis’ products. The Grant is based upon a budget provided to Novartis by Grant Recipient reflecting a good faith estimate of the actual cost of the Grant Activity. The Grant has not been determined in a manner that takes into account the volume or value of referrals or business, if any, generated between Novartis and Grant Recipient or any of their respective officers, directors, employees, agents, affiliates, parents or subsidiaries.
- 1.3 **Novartis Responsibility.** Grant Recipient agrees that Novartis’ responsibility is solely to provide the Grant. Novartis will not be liable to Grant Recipient or to any other person for the Grant Activity or the use of the Grant (including any claims or losses related thereto). Novartis may terminate this Agreement and require Grant Recipient to return the Grant and take other corrective action if Grant Recipient breaches this Agreement.

[DK1812940038](#)



## 2. OBLIGATIONS OF GRANT RECIPIENT

### 2.1 Use of Grant.

- (a) Grant Recipient verifies by signing this Agreement that the Grant Recipient is willing to receive the Grant.
- (b) Grant Recipient has appointed Activity and Amount Manager(s) to manage the Grant and the Grant Activities as set forth in Exhibit A.
- (c) Grant Recipient shall use the Grant solely for the Grant Activity and shall not use the Grant for any activity that is inconsistent with, or prohibited by any law, rule or regulation. The Grant Recipient undertakes to independently contact Novartis in the event any part of the Grant has not been used for the Grant Activity so that such amount can be refunded to Novartis without undue delay.
- (d) Grant Recipient will comply with (and shall be solely responsible for any failure to comply with) all relevant laws, rules and regulations (including any code of practice or other guidelines generally followed by pharmaceutical companies in the relevant country) in connection with the Grant Activity. Grant Recipient warrants that the Grant Activity is compliant with all such requirements.
- (e) Grant Recipient is solely responsible for the manner in which the Grant is disbursed, recorded and accounted and for all contractual and other relationships with third parties relating to the Grant Activity and the use of the Grant. Any claims for payment from third parties involved in the Grant Activity are the sole responsibility of Grant Recipient and Novartis will not fund any additional amounts for the Grant Activity.

### 2.2 Objectivity & Balance.

The Grant Activity will be independent, non-promotional and free from commercial influence or bias.

- (a) If the Grant Activity involves the discussion of Novartis products, or the comparison of Novartis products with other products, that discussion and/or comparison must be objective, balanced, accurate, not misleading or deceptive and in compliance with all applicable laws, rules and regulations. Where appropriate, the Grant Activity will include a discussion of multiple treatment options, and will not focus on a single product.
- (b) Grant Recipient will ensure that any titles or overview information relating to the Grant Activity will fairly and accurately represent the scope of the planned activity.
- (c) If required, Grant Recipient is responsible for selection of presenters, moderators and collaborators for the Grant Activity. Novartis will not control the planning, content, speaker selection or execution of any Grant Activity. If Novartis suggests presenters, moderators or

[DK1812940038](#)



collaborators, Grant Recipient will record the role of Novartis in making the suggestion, seek other sources and make a final selection based on balance and independence.

### 2.3 Disclosure of Financial Relationships.

- (a) Grant Recipient will: (i) disclose, to all audiences and in all publications relating to the Grant Activity, that Novartis has provided a grant to support the Grant Activity; (ii) acknowledge support from Novartis in brochures, syllabi, and other materials related to the Grant Activity; and (iii) disclose any other relationships Novartis has with any individual speakers, moderators, collaborators or Grant Recipient which a reasonable and ethical person would expect to be disclosed.
- (b) Novartis may disclose publicly the financial and non-financial support provided to Grant Recipient, including, without limitation, the Grant Recipient's identity, the Grant and purpose of the support.

### 2.4 Ancillary Activities.

- (a) If the Grant Activity occurs as part of an overall activity that includes commercial activities, such activities will neither influence planning nor interfere with the Grant Activity. No commercial activities will be permitted in the same room as an educational activity, unless (i) this is allowed in the country in which the activity will take place and (ii) only to the extent that such commercial activity does not interfere with the purpose of the Grant Activity.
- (b) The scheduling of meals and/or receptions, if any, in connection with any portion of the Grant Activity is at the sole discretion of Grant Recipient. Meals and/or receptions, if any, will be modest and conducive to the Grant Activity, and the amount of time at the meals or receptions will be clearly subordinate to the overall amount of time.
- (c) Reconciliation of Expenses. At the conclusion of the Grant Activity, Grant Recipient will provide to Novartis a reconciliation of the actual expenses versus estimated expenses and will issue a refund to Novartis for any portion of the Grant not incurred in the implementation of the Grant Activity. In addition, Grant Recipient will retain appropriate records of the Grant Activity and the use of the Grant and will provide copies of the records to Novartis on request to confirm that the Grant has been used in accordance with this Agreement.

## 3. GENERAL

- 3.1 **Entire Agreement.** This Agreement, together with its Exhibits, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter. In the event of any conflict between a substantive provision of this Agreement and any Exhibit hereto, the substantive provisions of this Agreement shall prevail.
- 3.2 **Governing Law and Jurisdiction.** This Agreement shall be governed by and construed under the laws of Denmark, without giving effect to the conflicts of laws provision thereof. Any dispute or claim arising out of or in connection with this Agreement which cannot be settled amicably between the Parties, is to be

[DK1812940038](#)



brought before the Maritime and Commercial Court in Copenhagen or, if this court is not competent, before a competent court of law in the Kingdom of Denmark.

3.3 **Counterparts.** This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives.

**NOVARTIS HEALTHCARE A/S**

**BISPEBJERG HOSPITAL**

DocuSigned by:  
**Rasmus Boye Kjellerup**  
By: \_\_\_\_\_  
FFAA384DC5B14F8...  
Date: 31-Jan-2019 | 5:03:16 AM EST

Read and acknowledged by:  
**Simon Francis Thomsen**  
By: \_\_\_\_\_  
3A8674BE07874F9...  
Date: 01-Feb-2019 | 3:55:12 AM EST

Name: Rasmus Boye Kjellerup  
Title: Medical Advisor, IHD, Denmark

Name: Simon Francis Thomsen  
Title: Professor, Chair of Dept. of Dermatology

DocuSigned by:  
**Nanna Dam**  
By: \_\_\_\_\_  
E250C16C94C94B3...  
Date: 31-jan-2019 | 4:07:56 AM EST

DocuSigned by:  
**Kirsten Wisborg**  
By: \_\_\_\_\_  
2F77E2B69D0F4E1...  
Date: 01-Feb-2019 | 7:31:26 AM EST

Name: Nanna Dam  
Title: Franchise Head, IHD, Denmark

Name: Kirsten Wisborg  
Title: Deputy director of Bispebjerg Hospital

DK1812940038



**EXHIBIT A**

**GRANT & GRANT ACTIVITY**

Grant amount: 92.400 DKK

Grant Activity: This Grant is given to support the collection of data from patients with chronic urticaria as specified in the supplemented application in Exhibit B, which contains a detailed breakdown of how the funds over a period of 12 month will be used, i.e. Preparation of forms and evaluation scheme, Data collection, Typing in of data, Database maintenance.

The Grant amount is payable against the corresponding invoice within sixty (60) days of its receipt and at the end of a calendar month.

The invoice shall include all details (including a Purchase Order Number) as specified in the Purchase Order.

[DK1812940038](#)



EXHIBIT B

## GRANT REQUEST LETTER INCLUDING BUDGET

København, d. 12. november 2018

Novartis A/S  
Edvard Thomsens Vej 14, 3.  
2300 København S

### Specifikation af det ansøgte beløb

Jeg fremsender hermed specificeret beskrivelse af den tidligere ansøgning omhandlende dataindsamling om kronisk urticaria.

Specifikt søger vi midler til at udføre en generel dataindsamling om patienter med kronisk urticaria. Vi har på Dermatologisk Afdeling, Bispebjerg Hospital specialfunktion for patienter med kronisk urticaria og har netop opnået status som GA<sup>2</sup>LEN Urticaria Center of Reference and Excellence (UCARE). Vi modtager ca. 200 patienter årligt til udredning og behandling for kronisk urticaria, og det er disse patienter, vi ønsker systematisk at indsamle data på. Dette vil muliggøre evt. senere analyser. Formålet er at indsamle data om:

- Sygdomskaraktetika (diagnose; CSU, CINDU, debutalder, familiær disposition)
- Sygdomsbyrde/symptomer (UAS7, UCT, VAS)
- Medicinforbrug
- Angioødem
- Rygning
- Komorbiditeter (hypertension, diabetes og fedme, psykiske sygdomme, gigtsygdomme, stofskiftesygdomme, atopiske sygdomme, øvrige sygdomme)
- Livskvalitet (DLQI, CU-Q2oL)
- Effekt af medicinsk behandling på symptomer og livskvalitet

Vi ønsker at indtaste disse oplysninger i en omfattende patientdatabase.

Med venlig hilsen

Simon Francis Thomsen, ledende overlæge, professor, dr.med.  
Dermatologisk afdeling  
Bispebjerg Hospital  
Telefon: 2613 9838  
E-mail: [simonfrancisthomsen@gmail.com](mailto:simonfrancisthomsen@gmail.com)

DK1812940038



**Nyt samlet budget**

Klargøring af skemaer og vurderingsinstrumenter

Løn, videnskabelig medhjælp, 12 måneder x 6 timer = 72 timer á 150 kr. = 10.800 kr.

Dataindsamling

Løn, videnskabelig medarbejder, 12 måneder x 20 timer = 240 timer á 250 kr. = 60.000 kr.

Dataindtastning

Løn videnskabelig medhjælp, 12 måneder x 8 timer = 96 timer á 150 kr. = 14.400 kr.

Databasevedligeholdelse

Løn, videnskabelig medhjælp, 12 måneder x 4 timer = 48 timer á 150 kr. = 7.200 kr.

**I alt**

**92.400 kr.**

Med venlig hilsen

Simon Francis Thomsen, ledende overlæge, professor, dr.med.

Dermatologisk afdeling

Bispebjerg Hospital

Telefon: 2613 9838

E-mail: [simonfrancisthomsen@gmail.com](mailto:simonfrancisthomsen@gmail.com)

**Insert from e-mail received 19 Dec 2018:**

1) Bank details (account number, name of account holder, name of bank)?

Reg.nr. 3100 konto. 3100130564 (account holder: Bispebjerg Hospital), PSP: F-12210-01-86-01 (specific account number, Simon Francis Thomsen). Danske Bank.

DK1812940038